-
Amivantamab, sold
under the
brand name Rybrevant, is a
bispecific monoclonal antibody used to
treat non-small cell lung cancer.
Amivantamab is a bispecific...
-
adverse reactions include rash, nail toxicity, infusion-related
reactions (
amivantamab),
musculoskeletal pain, edema, stomatitis,
venous thromboembolism, paresthesia...
-
treatment of
relapsing remitting multiple sclerosis (Novartis)
Rybrevant (
amivantamab) for the
treatment of non-small-cell lung
cancer (EGFR exon 20 insertion...
-
bispecific antibody drugs have
since been
approved by the US FDA: emicizumab,
amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab, epcoritamab, glofitamab...
- 1186/s13046-015-0207-9. PMC 4559261. PMID 26338018. "FDA
approves lazertinib with
amivantamab-vmjw for non-small lung cancer". U.S. Food and Drug
Administration (FDA)...
-
mafodotin L01FX16
Oportuzumab monatox L01FX17
Sacituzumab govitecan L01FX18
Amivantamab L01FX19
Sabatolimab L01FX20
Tremelimumab L01FX21
Naxitamab L01FX22 Loncastuximab...
- (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab ozogamicin)
Other Amivantamab Atezolizumab (+hyaluronidase)
Avelumab Axatilimab Belantamab mafodotin...
-
colorectal cancer (diagnosis)
Amatuximab mab
chimeric mesothelin cancer Amivantamab Rybrevant BsAb
human Epidermal growth factor receptor (EGFR), cMet Y...
-
Union and was
later withdrawn for
commercial reasons.
Others include amivantamab, blinatumomab, teclistamab, and emicizumab.
Since 2000, the therapeutic...
-
disease Bupivacaine/meloxicam
Heron Therapeutics postsurgical analgesia Amivantamab Janssen Biotech non-small cell lung
cancer with EGFR exon 20 insertion...
